Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota

doi:10.12114/j.issn.1007-9572.2022.0651

Abstract

Abstract:

Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease, represents a spectrum of nonalcoholic hepatic steatosis, nonalcoholic steatohepatitis, liver cirrhosis and hepatocellular carcinoma. Recent studies have revealed that the gut-liver axis is associated with the development of NAFLD. Intervention measures such as exercise, diet, microecological preparations, antibiotics, fecal microbiota transplantation and bacteriophage can alleviate NAFLD by improving intestinal microbiota. We reviewed recent advances in the relationship and mechanism between intestinal microbiota and NAFLD as well as treatment of NAFLD targeting the intestinal microbiota, and summarized that intestinal microbiota is closely related to NAFLD, and the regulation of intestinal microbiota can be used as a new target for NAFLD treatment, which will provide new ideas and references for clinicians in the diagnosis and treatment of NAFLD.

Key words: Non-alcoholic fatty liver disease, Gastrointestinal microbiome, Intestinal flora, Therapy, Metabolic syndrome, Microecological preparation, Fecal microbiota transplantation

摘要：

非酒精性脂肪性肝病（NAFLD）是最常见的慢性肝脏疾病，其疾病谱主要包括非酒精性肝脂肪变、非酒精性脂肪性肝炎（NASH）、肝硬化及肝细胞癌（HCC）。近年研究揭示肠-肝轴与NAFLD发生、发展相关，运动、饮食、微生态制剂、抗生素、粪菌移植、噬菌体等干预措施均可以通过改变肠道菌群缓解NAFLD。本文综述了肠道菌群与NAFLD的关系和作用机制及以调整肠道菌群为NAFLD治疗靶点的研究进展，发现肠道菌群与NAFLD密切相关，调控肠道菌群可作为NAFLD治疗的新靶点，将为临床医师治疗NAFLD提供新的思路和参考。

关键词: 非酒精性脂肪性肝病, 胃肠道微生物组, 肠道菌群, 治疗, 代谢综合征, 微生态制剂, 粪菌移植

FU Weiqiang,ZHOU Jianbo,WU Xiongjian, et al. Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota[J]. Chinese General Practice, 2023, 26(06): 742-748. DOI: 10.12114/j.issn.1007-9572.2022.0651.
傅伟强,周剑波,吴雄健等. 肠道菌群视角下非酒精性脂肪性肝病的治疗策略[J]. 中国全科医学, 2023, 26(06): 742-748. DOI: 10.12114/j.issn.1007-9572.2022.0651.

Figures/Tables 1

References 66

[1]	POWELL E E, WONG V W S, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet，2021，397(10290):2212-2224. DOI：10.1016/S0140-6736(20)32511-3.
[2]	CARIOU B, BYRNE C D, LOOMBA R，et al. Nonalcoholic fatty liver disease as a metabolic disease in humans：a literature review[J]. Diabetes Obes Metab，2021，23(5):1069-1083. DOI：10.1111/dom.14322.
[3]	MÉNDEZ-SÁNCHEZ N, DÍAZ-OROZCO L E. Editorial：international consensus recommendations to replace the terminology of non-alcoholic fatty liver disease （NAFLD） with metabolic-associated fatty liver disease （MAFLD）[J]. Med Sci Monit，2021，27:e933860. DOI：10.12659/MSM.933860.
[4]	GE X J, ZHENG L M, WANG M，et al. Prevalence trends in non-alcoholic fatty liver disease at the global，regional and national levels，1990-2017：a population-based observational study[J]. BMJ Open，2020，10(8):e036663. DOI：10.1136/bmjopen-2019-036663.
[5]	AHMAD M I, KHAN M U, KODALI S，et al. Hepatocellular carcinoma due to nonalcoholic fatty liver disease：current concepts and future challenges[J]. J Hepatocell Carcinoma，2022，9:477-496. DOI：10.2147/JHC.S344559.
[6]	NOUREDDIN M, SANYAL A J. Pathogenesis of NASH：the impact of multiple pathways[J]. Curr Hepatol Rep，2018，17(4):350-360. DOI：10.1007/s11901-018-0425-7.
[7]	KIM W, KIM B G, LEE J S，et al. Randomised clinical trial：the efficacy and safety of oltipraz，a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther，2017，45(8):1073-1083. DOI：10.1111/apt.13981.
[8]	HOOZEMANS J, DE BRAUW M, NIEUWDORP M，et al. Gut microbiome and metabolites in patients with NAFLD and after bariatric surgery：a comprehensive review[J]. Metabolites，2021，11(6):353. DOI：10.3390/metabo11060353.
[9]	VALLIANOU N, STRATIGOU T, CHRISTODOULATOS G S，et al. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders：current evidence and perspectives[J]. Curr Obes Rep，2019，8(3):317-332. DOI：10.1007/s13679-019-00352-2.
[10]	NOGACKA A M, GÓMEZ-MARTÍN M, SUÁREZ A，et al. Xenobiotics formed during food processing：their relation with the intestinal microbiota and colorectal cancer[J]. Int J Mol Sci，2019，20(8):E2051. DOI：10.3390/ijms20082051.
[11]	WAN M L Y, LING K H, EL-NEZAMI H，et al. Influence of functional food components on gut health[J]. Crit Rev Food Sci Nutr，2019，59(12):1927-1936. DOI：10.1080/10408398.2018.1433629.
[12]	OLIPHANT K, ALLEN-VERCOE E. Macronutrient metabolism by the human gut microbiome：major fermentation by-products and their impact on host health[J]. Microbiome，2019，7(1):91. DOI：10.1186/s40168-019-0704-8.
[13]	YAN X F, JIN J J, SU X H，et al. Intestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension[J]. Circ Res，2020，126(7):839-853. DOI：10.1161/CIRCRESAHA.119.316394.
[14]	ZHAO Y Z, ZHOU J L, LIU J Q，et al. Metagenome of gut microbiota of children with nonalcoholic fatty liver disease[J]. Front Pediatr，2019，7:518. DOI：10.3389/fped.2019.00518.
[15]	HOYLES L, FERNÁNDEZ-REAL J M, FEDERICI M，et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women[J]. Nat Med，2018，24(7):1070-1080. DOI：10.1038/s41591-018-0061-3.
[16]	YUAN J, CHEN C, CUI J H，et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae[J]. Cell Metab，2019，30(6):1172. DOI：10.1016/j.cmet.2019.11.006.
[17]	SHARPTON S R, AJMERA V, LOOMBA R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease：from composition to function[J]. Clin Gastroenterol Hepatol，2019，17(2):296-306. DOI：10.1016/j.cgh.2018.08.065.
[18]	DE MUNCK T J I, XU P, VERWIJS H J A，et al. Intestinal permeability in human nonalcoholic fatty liver disease：a systematic review and meta-analysis[J]. Liver Int，2020，40(12):2906-2916. DOI：10.1111/liv.14696
[19]	CHEN J, ZHENG M H, LIU J，et al. Ratio of conjugated chenodeoxycholic to muricholic acids is associated with severity of nonalcoholic steatohepatitis[J]. Obesity （Silver Spring），2019，27(12):2055-2066. DOI：10.1002/oby.22627.
[20]	JI Y, YIN Y, SUN L J，et al. The molecular and mechanistic insights based on gut-liver axis：nutritional target for non-alcoholic fatty liver disease （NAFLD） improvement[J]. Int J Mol Sci，2020，21(9):E3066. DOI：10.3390/ijms21093066.
[21]	ZHAO S, JANG C, LIU J，et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate[J]. Nature，2020，579(7800):586-591. DOI：10.1038/s41586-020-2101-7.
[22]	VIVEIROS K. The role of life style modifications in comprehensive non-alcoholic fatty liver disease treatment[J]. Clin Liver Dis （Hoboken），2021，17(1):11-14. DOI：10.1002/cld.1007.
[23]	BARTON W, PENNEY N C, CRONIN O，et al. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level[J]. Gut，2018，67(4):625-633. DOI：10.1136/gutjnl-2016-313627.
[24]	VALLIANOU N, DALAMAGA M, STRATIGOU T，et al. Do antibiotics cause obesity through long-term alterations in the gut microbiome? A review of current evidence[J]. Curr Obes Rep，2021，10(3):244-262. DOI：10.1007/s13679-021-00438-w.
[25]	CARBAJO-PESCADOR S, PORRAS D, GARCÍA-MEDIAVILLA M V，et al. Beneficial effects of exercise on gut microbiota functionality and barrier integrity，and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease[J]. Dis Model Mech，2019，12(5):dmm039206. DOI：10.1242/dmm.039206.
[26]	CHENG R T, WANG L, LE S L，et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease[J]. Nat Commun，2022，13(1):2555. DOI：10.1038/s41467-022-29968-0.
[27]	VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLA-BERTOT L，et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology，2015，149(2):367-378.e5;quize14-15. DOI：10.1053/j.gastro.2015.04.005.
[28]	SAVARD C, TARTAGLIONE E V, KUVER R，et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis[J]. Hepatology，2013，57(1):81-92. DOI：10.1002/hep.25789.
[29]	CHALASANI N, YOUNOSSI Z, LAVINE J E，et al. The diagnosis and management of nonalcoholic fatty liver disease：practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology，2018，67(1):328-357. DOI：10.1002/hep.29367.
[30]	ALLER R, BURGUEÑO GOMEZ B, SIGÜENZA R，et al. Comparative study of overweight and obese patients with nonalcoholic fatty liver disease[J]. Rev Esp Enferm Dig，2019，111(4):256-263. DOI：10.17235/reed.2019.5926/2018.
[31]	CALABRESE F M, DISCIGLIO V, FRANCO I，et al. A low glycemic index Mediterranean diet combined with aerobic physical activity rearranges the gut microbiota signature in NAFLD patients[J]. Nutrients，2022，14(9):1773. DOI：10.3390/nu14091773.
[32]	HILL C, GUARNER F, REID G，et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nat Rev Gastroenterol Hepatol，2014，11(8):506-514. DOI：10.1038/nrgastro.2014.66.
[33]	MOHAMAD NOR M H, AYOB N, MOKHTAR N M，et al. The effect of probiotics （MCP® BCMC® strains） on hepatic steatosis，small intestinal mucosal immune function，and intestinal barrier in patients with non-alcoholic fatty liver disease[J]. Nutrients，2021，13(9):3192. DOI：10.3390/nu13093192.
[34]	LUO M M, YAN J B, WU L Y，et al. Probiotics alleviated nonalcoholic fatty liver disease in high-fat diet-fed rats via gut microbiota/FXR/FGF15 signaling pathway[J]. J Immunol Res，2021，2021:2264737. DOI：10.1155/2021/2264737.
[35]	PARK E J, LEE Y S, KIM S M，et al. Beneficial effects of Lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat/high fructose diet-fed rats[J]. Nutrients，2020，12(2):E542. DOI：10.3390/nu12020542.
[36]	AHN S B, JUN D W, KANG B K，et al. Randomized，double-blind，placebo-controlled study of a multi species probiotic mixture in nonalcoholic fatty liver disease[J]. Sci Rep，2019，9(1):5688. DOI：10.1038/s41598-019-42059-3.
[37]	DUSEJA A, ACHARYA S K, MEHTA M，et al. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease （NAFLD）：a randomised，double-blind，proof of concept study[J]. BMJ Open Gastroenterol，2019，6(1):e000315. DOI：10.1136/bmjgast-2019-000315.
[38]	LAVEKAR A S, V RAJE D, MANOHAR T，et al. Role of probiotics in the treatment of nonalcoholic fatty liver disease：a meta-analysis[J]. Euroasian J Hepatogastroenterol，2017，7(2):130-137. DOI：10.5005/jp-journals-10018-1233.
[39]	HOLSCHER H D. Dietary fiber and prebiotics and the gastrointestinal microbiota[J]. Gut Microbes，2017，8(2):172-184. DOI：10.1080/19490976.2017.1290756.
[40]	PLOVIER H, EVERARD A, DRUART C，et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice[J]. Nat Med，2017，23(1):107-113. DOI：10.1038/nm.4236.
[41]	SINGH D P, KHARE P, ZHU J，et al. A novel cobiotic-based preventive approach against high-fat diet-induced adiposity，nonalcoholic fatty liver and gut derangement in mice[J]. Int J Obes （Lond），2016，40(3):487-496. DOI：10.1038/ijo.2015.197.
[42]	BOMHOF M R, PARNELL J A, RAMAY H R，et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic：a pilot clinical trial[J]. Eur J Nutr，2019，58(4):1735-1745. DOI：10.1007/s00394-018-1721-2.
[43]	CHONG P L, LAIGHT D, ASPINALL R J，et al. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease[J]. BMC Gastroenterol，2021，21(1):144. DOI：10.1186/s12876-021-01660-5.
[44]	KOBYLIAK N, ABENAVOLI L, MYKHALCHYSHYN G，et al. A multi-strain probiotic reduces the fatty liver index，cytokines and aminotransferase levels in NAFLD patients：evidence from a randomized clinical trial[J]. J Gastrointestin Liver Dis，2018，27(1):41-49. DOI：10.15403/jgld.2014.1121.271.kby.
[45]	MOFIDI F, POUSTCHI H, YARI Z，et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease：a pilot，randomised，double-blind，placebo-controlled，clinical trial[J]. Br J Nutr，2017，117(5):662-668. DOI：10.1017/S0007114517000204.
[46]	SCORLETTI E, AFOLABI P R, MILES E A，et al. Synbiotics alter fecal microbiomes，but not liver fat or fibrosis，in a randomized trial of patients with nonalcoholic fatty liver disease[J]. Gastroenterology，2020，158(6):1597-1610.e7. DOI：10.1053/j.gastro.2020.01.031.
[47]	FEROLLA S M, COUTO C A, COSTA-SILVA L，et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters，but not on gut permeability in a population with nonalcoholic steatohepatitis[J]. Nutrients，2016，8(7):397. DOI：10.3390/nu8070397.
[48]	VALLIANOU N, STRATIGOU T, CHRISTODOULATOS G S，et al. Probiotics，prebiotics，synbiotics，postbiotics，and obesity：current evidence，controversies，and perspectives[J]. Curr Obes Rep，2020，9(3):179-192. DOI：10.1007/s13679-020-00379-w.
[49]	VALLEJO-CORDOBA B, CASTRO-LÓPEZ C, GARCÍA H S，et al. Postbiotics and paraprobiotics：a review of current evidence and emerging trends[J]. Adv Food Nutr Res，2020，94:1-34. DOI：10.1016/bs.afnr.2020.06.001.
[50]	PELUZIO M D C G, MARTINEZ J A, MILAGRO F I. Postbiotics：metabolites and mechanisms involved in microbiota-host interactions[J]. Trends Food Sci Technol，2021，108:11-26. DOI：10.1016/j.tifs.2020.12.004.
[51]	WANG S H, AHMADI S, NAGPAL R，et al. Lipoteichoic acid from the cell wall of a heat killed Lactobacillus paracasei D3-5 ameliorates aging-related leaky gut，inflammation and improves physical and cognitive functions：from C. elegans to mice[J]. Geroscience，2020，42(1):333-352. DOI：10.1007/s11357-019-00137-4.
[52]	MA L Y, NI Y H, WANG Z，et al. Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice[J]. Gut Microbes，2020，12(1):1-19. DOI：10.1080/19490976.2020.1832857.
[53]	中华医学会肠外肠内营养学分会，中国国际医疗保健促进交流会加速康复外科分会，中国微生态治疗创新联盟，等. 菌群移植标准化方法学的建立与临床应用中国专家共识[J]. 中华胃肠外科杂志，2020，23(S1):5-13. DOI：10.3760/cma.j.cn.441530-20200420-00231.
[54]	ZHOU D, PAN Q, SHEN F，et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep，2017，7(1):1529. DOI：10.1038/s41598-017-01751-y.
[55]	VRIEZE A, VAN NOOD E, HOLLEMAN F，et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J]. Gastroenterology，2012，143(4):913-916.e7. DOI：10.1053/j.gastro.2012.06.031.
[56]	WITJES J J, SMITS L P, PEKMEZ C T，et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis[J]. Hepatol Commun，2020，4(11):1578-1590. DOI：10.1002/hep4.1601.
[57]	CRAVEN L, RAHMAN A, NAIR PARVATHY S，et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability：a randomized control trial[J]. Am J Gastroenterol，2020，115(7):1055-1065. DOI：10.14309/ajg.0000000000000661.
[58]	KAJI K, TAKAYA H, SAIKAWA S，et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity[J]. World J Gastroenterol，2017，23(47):8355-8366. DOI：10.3748/wjg.v23.i47.8355.
[59]	JIAN J, NIE M T, XIANG B Y，et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids[J]. Front Pharmacol，2022，13:841132. DOI：10.3389/fphar.2022.841132.
[60]	FUJINAGA Y, KAWARATANI H, KAYA D，et al. Effective combination therapy of angiotensin-Ⅱ receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis[J]. Int J Mol Sci，2020，21(15):E5589. DOI：10.3390/ijms21155589.
[61]	GANGARAPU V, INCE A T, BAYSAL B，et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol，2015，27(7):840-845. DOI：10.1097/MEG.0000000000000348.
[62]	COBBOLD J F L, ATKINSON S, MARCHESI J R，et al. Rifaximin in non-alcoholic steatohepatitis：an open-label pilot study[J]. Hepatol Res，2018，48(1):69-77. DOI：10.1111/hepr.12904.
[63]	SUN D L, ZUO C, HUANG W，et al. Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice[J]. J Antibiot （Tokyo），2022，75(6):341-353. DOI：10.1038/s41429-022-00522-w.
[64]	MAHANA D, TRENT C M, KURTZ Z D，et al. Antibiotic perturbation of the murine gut microbiome enhances the adiposity，insulin resistance，and liver disease associated with high-fat diet[J]. Genome Med，2016，8(1):48. DOI：10.1186/s13073-016-0297-9.
[65]	GÓRSKI A, BOLLYKY P L, PRZYBYLSKI M，et al. Perspectives of phage therapy in non-bacterial infections[J]. Front Microbiol，2018，9:3306. DOI：10.3389/fmicb.2018.03306.
[66]	DUAN Y, LLORENTE C, LANG S，et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease[J]. Nature，2019，575(7783):505-511. DOI：10.1038/s41586-019-1742-x.